There could be more at stake for Pfizer in its UK Supreme Court pregabalin patent dispute than was previously thought. A recently-released study argues that if the pharma company loses the case, it will be liable to pay the National Health Service (NHS) £502 million in compensation.

Want to read more?

Register to access two of our subscriber-only articles per month

Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts

Already registered? Log in

What our customers are saying

IAM explores how businesses can leverage IP rights as real assets beyond their traditional use. As the magazine addresses IP management issues without overly dwelling on legal matters, I consider it an eminently useful reference for innovative business executives.

Dr Frank Cuypers
Consulting actuary
PricewaterhouseCoopers

Benefits

Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.

Why subscribe?